Ningfei An University of Chicago
1 protocol

Yubin Kang
  • Division of Hematology-Oncology, Department of Medicine, Medical University of South Carolina, USA
  • 1 Author merit


M.D. in Hematology, Shanghai Second Military Medical University, China, 1991

Current position

Assistant Professor, Department of Medicine/Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina

Publications (selected from 39 papers)

  1. An, N., Janech, M., Bland, A., Lazarchick, J., Arthur, J. and Kang, Y. (2013). Proteomic analysis of murine bone marrow niche microenvironment identifies thioredoxin as a novel agent for radioprotection and for enhancing donor cell reconstitution. Exp Hematol.
  2. An, N., Lin, Y. W., Mahajan, S., Kellner, J. N., Wang, Y., Li, Z., Kraft, A. S. and Kang, Y. (2013). Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells. Stem Cells 31(6): 1202-1212.
  3. An, N., Kraft, A. S. and Kang, Y. (2013). Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. J Hematol Oncol 6: 12.
  4. An, N. and Kang, Y. (2013). Using quantitative real-time PCR to determine donor cell engraftment in a competitive murine bone marrow transplantation model. J Vis Exp(73): e50193.
  5. Costa, L. J.*, Kramer, C., Hogan, K. R., Butcher, C. D., Littleton, A. L., Shoptaw, K. B., Kang, Y.* and Stuart, R. K. (2012). Pegfilgrastim‐versus filgrastim‐based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion 52(11): 2375-2381. *Co-first authorship
  6. Costa, L. J., Abbas, J., Hogan, K. R., Kramer, C., McDonald, K., Butcher, C. D., Littleton, A., Shoptaw, K., Kang, Y. and Stuart, R. K. (2012). Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant 47(11): 1403-1408.
  7. Butler, C., Wolff, D. J., Kang, Y., Stuart, R. K. and Costa, L. J. (2012). Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients. Leuk Lymphoma 53(12): 2444-2448.
  8. Zhou, D., Deoliveira, D., Kang, Y., Choi, S. S., Li, Z., Chao, N. J. and Chen, B. J. (2013). Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation. Int J Radiat Oncol Biol Phys 85(4): 1141-1148.
  9. Costa, L. J., Abbas, J., Ortiz-Cruz, K. L., Kang, Y. and Stuart, R. K. (2012). Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. Eur J Haematol 89(5): 432-434.
  10. Kang, Y., Chen, B. J., Deoliveira, D., Mito, J. and Chao, N. J. (2010). Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model. PLoS One 5(6): e11316.
  11. Kang, Y., Moressi, C. J., Scheetz, T. E., Xie, L., Tran, D. T., Casavant, T. L., Ak, P., Benham, C. J., Davidson, B. L. and McCray, P. B., Jr. (2006). Integration site choice of a feline immunodeficiency virus vector. J Virol 80(17): 8820-8823.
  12. Kang, Y., Xie, L., Tran, D. T., Stein, C. S., Hickey, M., Davidson, B. L. and McCray, P. B., Jr. (2005). Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood 106(5): 1552-1558.
  13. Kang, Y.*, Stein, C. S.*, Heth, J. A., Sinn, P. L., Penisten, A. K., Staber, P. D., Ratliff, K. L., Shen, H., Barker, C. K., Martins, I., Sharkey, C. M., Sanders, D. A., McCray, P. B., Jr. and Davidson, B. L. (2002). In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J Virol 76(18): 9378-9388. *Co-first authorship
  14. Melo, M. E., Qian, J., El-Amine, M., Agarwal, R. K., Soukhareva, N., Kang, Y. and Scott, D. W. (2002). Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol 168(9): 4788-4795.
  15. Stein, C. S.*, Kang, Y.*, Sauter, S. L., Townsend, K., Staber, P., Derksen, T. A., Martins, I., Qian, J., Davidson, B. L. and McCray, P. B., Jr. (2001). In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Mol Ther 3(6): 850-856. *Co-first authorship
  16. El-Amine, M., Melo, M., Kang, Y., Nguyen, H., Qian, J. and Scott, D. W. (2000). Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. J Immunol 165(10): 5631-5636.
  17. Agarwal, R. K., Kang, Y., Zambidis, E., Scott, D. W., Chan, C. C. and Caspi, R. R. (2000). Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest 106(2): 245-252. (Commentary by George C. Tsoko and Gerald T. Nepom, “Gene therapy in the treatment of autoimmune diseases”, J. Clin. Invest. 106:181-183).
  18. Kang, Y., Melo, M., Deng, E., Tisch, R., El-Amine, M. and Scott, D. W. (1999). Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness. Proc Natl Acad Sci U S A 96(15): 8609-8614.
  19. Kang, Y., Melo, E. F. and Scott, D. W. (1998). An ongoing immune response to HIV envelope gp120 in human CD4-transgenic mice contributes to T cell decline upon intravenous administration of gp120. Eur J Immunol 28(8): 2253-2264.
1 Protocol published
In vivo BrdU Incorporation Assay for Murine Hematopioetic Stem Cells
Authors:  Ningfei An and Yubin Kang, date: 11/05/2013, view: 6417, Q&A: 0
Bromodeoxyuridine (BrdU) is a thymidine analog that is incorporated into DNA during the S-phase of the cell cycle. As such, BrdU incorporation can be used to quantify the number of cells that are in S-phase in the time period during which BrdU is ...